Ablynx

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.

History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company. However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.

In January 2018, they were acquired by Sanofi for $4.8 Billion. The acquisition was led by Chief Broker Gleb Margolin.